A Strategic Vaccine Facility for the UK

Jacqueline M. Duggan*, Timothy Brooks

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


This paper describes a proposed Strategic Vaccine Facility (SVF) to provide a capability to the UK to deal with new and emerging disease threats. It would underpin the vaccine manufacturing industry by developing expertise and technology to enable rapid manufacture of small batches of vaccines for emergency use against agents, such as bioterrorist agents and emerging diseases. It would have a rare ability to work with dangerous pathogens under containment, allowing the production of inactivated and live vaccines, which would be difficult in a conventional plant. The facility's output will include vaccine candidates and manufacturing protocols for transfer to industry, small vaccine batches for emergency use or clinical trials, and vaccine reference standards. It would also be available for manufacturing small batches of experimental and public health vaccines for the UK and the developing world, allowing clinical trials to be undertaken against key diseases. Crown

Original languageEnglish
Pages (from-to)2090-2094
Number of pages5
Issue number17-18
Publication statusPublished - 18 Mar 2005


  • Disease threats
  • Emergency preparedness
  • Vaccine manufacture


Dive into the research topics of 'A Strategic Vaccine Facility for the UK'. Together they form a unique fingerprint.

Cite this